Squadron Capital Management LLC
Squadron Capital Management LLC reported 45 holdings worth US$398M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Squadron Capital Management LLC reported 45 holdings worth US$398M as of Sep 30, 2026. Largest: Kodiak Sciences Inc, C4 Therapeutics, Inc. and Cogent Biosciences, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 45
- Value as reported
- US$398M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Kodiak Sciences Inc | 420K | US$39.8M | 10.0% |
| C4 Therapeutics, Inc. | 9.32M | US$31M | 7.8% |
| Cogent Biosciences, Inc. | 915K | US$29.3M | 7.4% |
| Silence Therapeutics PLC | 2.08M | US$22.8M | 5.7% |
| Zentalis Pharmaceuticals, Inc. | 6.83M | US$18.9M | 4.7% |
| Edgewise Therapeutics, Inc. | 425K | US$17.3M | 4.3% |
| Relay Therapeutics, Inc. | 785K | US$14.2M | 3.6% |
| ORIC Pharmaceuticals, Inc. | 1M | US$13.5M | 3.4% |
| Relmada Therapeutics, Inc. | 3.5M | US$13.2M | 3.3% |
| Definium Therapeutics, Inc. | 340K | US$12.9M | 3.2% |
| Adlai Nortye Group Ltd. | 765K | US$12.2M | 3.1% |
| Vera Therapeutics, Inc. | 305K | US$9.85M | 2.5% |
| Inventiva SA | 2.4M | US$8.86M | 2.2% |
| Avalo Therapeutics, Inc. | 450K | US$6.9M | 1.7% |
| Aclaris Therapeutics, Inc. | 1.2M | US$6.31M | 1.6% |
| Assembly Biosciences, Inc. | 225K | US$5.29M | 1.3% |
| Adagene, Inc. | 1.62M | US$5.17M | 1.3% |
| Crescent Biopharma, Inc. | 350K | US$5.11M | 1.3% |
| Zura Bio Limited | 1.2M | US$4.99M | 1.3% |
| TCGX Acquisition Corp. | 370K | US$4.63M | 1.2% |
| Contineum Therapeutics, Inc. | 324K | US$4.34M | 1.1% |
| Inhibikase Therapeutics, Inc. | 2M | US$4.11M | 1.0% |
| Palisade Bio, Inc. | 3M | US$4.05M | 1.0% |
| Tango Therapeutics, Inc. | 150K | US$3.74M | 0.94% |
| Janux Therapeutics, Inc. | 215K | US$3.72M | 0.93% |
| Savara, Inc. | 675K | US$3.48M | 0.87% |
| JATT III Acquisition Corp | 250K | US$2.75M | 0.69% |
| ALX Oncology Holdings Inc. | 1.4M | US$1.95M | 0.49% |
| Lipocine Inc. | 810K | US$1.78M | 0.45% |
| PepGen Inc. | 600K | US$1.45M | 0.36% |
| JATT II Acquisition Corp | 65,000 | US$731K | 0.18% |
| Enliven Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Forte Biosciences, Inc. | 0 | US$0 | 0.00% |
| InMed Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Maze Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Neumora Therapeutics, Inc. | 0 | US$0 | 0.00% |
| NextCure, Inc. | 0 | US$0 | 0.00% |
| Pasithea Therapeutics Corp. | 0 | US$0 | 0.00% |
| ProMIS Neurosciences Inc. | 0 | US$0 | 0.00% |
| Rezolute, Inc. | 0 | US$0 | 0.00% |
| BioAge Labs, Inc. | 0 | US$0 | 0.00% |
| CalciMedica, Inc. | 0 | US$0 | 0.00% |
| Cue Biopharma, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related